COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04787510

Enrollment

Registered

2021-03-08

Start date

2020-12-23

Completion date

2021-06-23

Last updated

2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Disease, Hospitalized Patients, SARS-COV2 Infection

Brief summary

Effect of Covid-19 disease in clotting factors levels in hospitalized patients

Detailed description

Effect of Covid-19 disease in clotting factors levels in hospitalized patients positive for sars-cov2 infection. Association between clotting factors levels and disease severity,morbidity and mortality in these patients. Effect of anticoagulant therapy in the clotting factors' levels in these patients

Interventions

DRUGlow molecular weight Heparin as standard of care treatment

STANDARD OF CARE

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* AGE\> 18 * SINGED INFORMED CONSENT FORM * POSITIVE PCR TEST FOR SARS-COV2 INFECTION * FINDINGS IN CXR OR CT OF THE LUNGS CONSISTENT WITH INFECTION OF LOWER RESPIRATORY TRACT

Exclusion criteria

* AGE\<18 * DENIAL TO PROVIDE INFORMED CONSENT FORM * HISTORY OF MALIGNANCY * PRIOR USE OF ANTICOAGULANT THERAPY * PRIOR USE OF STEROIDS LONGER THAN 14 DAYS * LACTATION-PREGNANCY

Design outcomes

Primary

Measure	Time frame	Description
EFFECT OF COVID-19 DISEASE IN CLOTTING FACTORS	6 MONTHS	leves of cloting factors before and after treatment with LMWH

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026